Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299438 | 0.92 | PTGS2 (0.49) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL1919590 | 0.90 | MEN1 (0.44) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL3398857 | 0.86 | PTGS2 (0.51) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2298446 | 0.86 | ALOX5 (0.53) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6119754 | 0.86 | MEN1 (0.44) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6119663 | 0.84 | MEN1 (0.44) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2297507 | 0.81 | L3MBTL1 (0.38) | ALDH1A1L3MBTL1TP53MAPTMEN1 | |
| SCHEMBL2297483 | 0.78 | PTGS2 (0.50) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL12940204 | 0.77 | PTGS2 (0.55) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL13457553 | 0.77 | MEN1 (0.48) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245023-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-8071797-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2245023-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009101022-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | WO | disclosed |
| US-20090208449-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208449-A1 | Heterocyclic antiviral compounds | EIF2AK2, HCCS, RTF2 | PTGS2 2072/4885KDM4E 2068/4885ALDH1A1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.